WINT News and Press, Windtree Therapeutics Inc. From 08/23/23

WARRINGTON, Pa., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today reported that the United States Pate...

WARRINGTON, PA / ACCESSWIRE / August 16, 2023 / Windtree Therapeutics, Inc. (NASDAQ:WINT) is a biotechnology company developing treatments for severe cardiovascular disorders. It is targeting patients with acute heart failure (AHF) and cardiogenic shock (CS), as heart failure remains one of the ...

2023-08-07 17:40:58 ET Windtree TherapeuticS press release ( NASDAQ: WINT ): Q2 GAAP EPS of -$1.64 misses by $0.96 . As of June 30, 2023, the Company reported cash and cash equivalents of $11.5 million, which is expected to be sufficient to support our development acti...

Company plans to initiate a Phase 2 SEISMiC extension study of istaroxime in early cardiogenic shock in Q3; Study start-up for a Phase 2 SCAI Stage C cardiogenic shock study underway Completed $12.4 million public offering including full exercise of overallotment option WARRIN...

WARRINGTON, PA / ACCESSWIRE / July 25, 2023 / Windtree Therapeutics Inc. (NASDAQ:WINT) is looking to revolutionize acute care treatment for patients with serious conditions like acute heart failure (AHF) and cardiogenic shock (CS). The congestive heart failure market is worth $6.7 billion, and ...

WARRINGTON, PA / ACCESSWIRE / July 18, 2023 / The global acute hospital care market was worth $3.2 trillion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5.62% from 2023 to 2030. By 2025, nearly half of the population is projected to be diagnosed with a chronic c...

WARRINGTON, PA / ACCESSWIRE / July 14, 2023 / Windtree Therapeutics, Inc. (NASDAQ:WINT), a biotechnology company treating late-stage acute cardiovascular disorders, is advancing its first-in-class drug for serious heart conditions. The company believes that this treatment - named Istaroxime - ca...

WARRINGTON, Pa., June 27, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced that the Company appointed...

WARRINGTON, Pa., June 12, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today reported that the United States Pate...

2023-06-05 16:35:14 ET Penny stocks often represent an intriguing opportunity for investors. Defined by the U.S. Securities and Exchange Commission as shares trading for less than $5, these stocks generally belong to small companies that may not yet have made their mark in the mainstream ma...